Sign in
Taking people in AustriaPhase 4

Tests cariprazine's effect on thinking skills in people with schizophrenia

Studies changes in thinking abilities in adults with schizophrenia starting cariprazine treatment.

Key facts

Who runs it
Medizinische Universitaet Innsbruck
Where
Innsbruck and Salzburg, AustriaSee the 2 sites
Registry title
An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment
Status
Recruiting
Phase
Phase 4
People taking part
20 people, planned
Started
21 Mar 2021
Expected to end
30 Jun 2028
Type of study
Interventional
Record updated
22 June 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with schizophrenia whose current oral antipsychotic treatment needs to be adjusted. It studies how cariprazine affects thinking skills.

Age
18-65 years
Sex
All sexes can join.
Disease stage
Schizophrenia (ICD-10). No hospital stay for worse psychosis and no change in drug treatment for at least 8 weeks. Needs a treatment adjustment, with a CGI-S baseline score of 4 or higher.
Earlier treatment
Must be on an oral antipsychotic that the treating psychiatrist says needs adjusting. Cannot have been treated with cariprazine before with poor response or side effects, or be on it now. Cannot be on clozapine now.

Main reasons for not taking part

  • Severe delusions, disorganized thinking or hallucinations (PANSS score of 5 or higher)
  • Mainly negative symptoms
  • Regular use of other brain-acting drugs, such as mood stabilizers or antidepressants
  • Pregnancy or breast-feeding
  • Active suicidal thoughts, alcohol or drug abuse, or IQ of 70 or less

The registry criteria, word for word

Show all 20 criteriaShow less

Who can take part

  • Diagnosis of schizophrenia as defined by ICD-10 as determined by the M.I.N.I
  • Age 18-65 years
  • Without hospitalization due to worsening of psychosis and without any modification in psychopharmacological treatment for at least 8 weeks
  • In need of adjustment of the current oral antipsychotic treatment as judged by the treating psychiatrist
  • CGI-S baseline score ≥ 4
  • Capable of providing written informed consent

Who cannot take part

  • Patients who participated in another trial with an investigational drug or cognitive-enhancing intervention within 90 days prior to screening
  • Regularly taking centrally active medications except antipsychotics (mood stabilizers, antidepressants, etc.)
  • Patients with contraindications to MRI (e.g. claustrophobia, pacemaker, non-MRI-compatible implants)
  • A diagnosis of alcohol and/or drug abuse or dependence as assessed through the M.I.N.I. or a positive UDS
  • Patients who are currently treated with cariprazine or have shown insufficient response or intolerance to cariprazine in the past
  • Current treatment with clozapine
  • A score of ≥ 5 on the PANSS items related to delusions (P1), conceptual disorganization (P2), and hallucinatory behavior (P3)
  • Patients who are not fluent in the language of the cognitive batteries and questionnaires
  • Pregnancy or breast-feeding
  • Presence of predominant negative symptoms (PANSS FSNS >24 and PANSS FSPS <19) to avoid pseudospecificity
  • Presence of clinically significant extrapyramidal symptoms, defined a score of ≥ 3 on one of the subscales of the St. Hans Rating Scale (global hyperkinesia subscale, global parkinsonism subscale, dystonia subscale, akathisia subscale) and/or the use of anticholinergics for the treatment of extrapyramidal motor symptoms
  • Presence of clinically significant symptoms of depression, defined as a total score of ≥ 11 on the CDSS
  • Active suicidal ideation as measured through the C-SSRS, defined as an answer of ‘Yes’ to items 4 and/or 5
  • IQ of 70 or less as assessed through the MWT-B

Where in Austria

  • Medizinische Universitaet InnsbruckInnsbruck, AustriaTaking people
  • Gemeinnuetzige Salzburger Landeskliniken Betriebsgesellschaft mbHSalzburg, AustriaTaking people

About the trial

What the trial wants to find out

The primary objective is to assess changes in cognitive functioning in schizophrenia patients starting treatment with cariprazine

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record

Print a page for my doctor

Data and sources

Registry record
Listed on the EU's official list of trials (CTIS).
Official title
An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment
Plain-language title
Tests cariprazine's effect on thinking skills in people with schizophreniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 9 November 2026.
Record updated
22 June 2026